Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Randomised, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of Once-Daily Orally Administered ZD4054 10 mg in Non-Metastatic Hormone-Resistant Prostate Cancer Patients

Next Previous
X
Search
Trial Profile

A Phase III, Randomised, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of Once-Daily Orally Administered ZD4054 10 mg in Non-Metastatic Hormone-Resistant Prostate Cancer Patients

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 20 Jan 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zibotentan (Primary)
  • Indications Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ENTHUSE-M0
  • Sponsors AstraZeneca

    • Most Recent Events

    • 22 Dec 2021 This trial has been completed in Belgium, according to European Clinical Trials Database record.
    • 05 Oct 2021 This trial has been completed in France, according to European Clinical Trials Database.
    • 17 Apr 2013 Planned number of patients changed from 1507 to 2496 as reported by German Clinical Trials Register.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top